346 related articles for article (PubMed ID: 29119942)
41. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
[TBL] [Abstract][Full Text] [Related]
42. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
[TBL] [Abstract][Full Text] [Related]
43. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
Basu S; Kung J; Houseni M; Zhuang H; Tidmarsh GF; Alavi A
Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):9-19. PubMed ID: 18337683
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
45. Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.
Ose N; Sawabata N; Minami M; Inoue M; Shintani Y; Kadota Y; Okumura M
Eur J Cardiothorac Surg; 2012 Jul; 42(1):89-92. PubMed ID: 22290887
[TBL] [Abstract][Full Text] [Related]
46. Prospective comparison of
Kirchner J; Sawicki LM; Nensa F; Schaarschmidt BM; Reis H; Ingenwerth M; Bogner S; Aigner C; Buchbender C; Umutlu L; Antoch G; Herrmann K; Heusch P
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):437-445. PubMed ID: 30074073
[TBL] [Abstract][Full Text] [Related]
47. Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer.
Lin JT; Yang XN; Zhong WZ; Liao RQ; Dong S; Nie Q; Weng SX; Fang XJ; Zheng JY; Wu YL
Eur J Cardiothorac Surg; 2016 Nov; 50(5):914-919. PubMed ID: 27113090
[TBL] [Abstract][Full Text] [Related]
48. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
[TBL] [Abstract][Full Text] [Related]
49. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
50. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
[TBL] [Abstract][Full Text] [Related]
51. Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.
Even AJG; Reymen B; La Fontaine MD; Das M; Jochems A; Mottaghy FM; Belderbos JSA; De Ruysscher D; Lambin P; van Elmpt W
Acta Oncol; 2017 Nov; 56(11):1591-1596. PubMed ID: 28840770
[TBL] [Abstract][Full Text] [Related]
52. 18F-FDG PET increases visibility of bone lesions in relapsed multiple myeloma: is this hypoxia-driven?
de Waal EG; Slart RH; Leene MJ; Kluin PM; Vellenga E
Clin Nucl Med; 2015 Apr; 40(4):291-6. PubMed ID: 25546223
[TBL] [Abstract][Full Text] [Related]
53. [Value of 18F-FETNIM PET-CT for detection of tumor hypoxia in non-small-cell lung cancer].
Hu M; Kong L; Zhao SQ; Yang GR; Yang WF; Han AQ; Fu Z; Ma L; Zheng JS; Yu JM
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):463-6. PubMed ID: 20819492
[TBL] [Abstract][Full Text] [Related]
54. Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer.
Sharma A; Mohan A; Bhalla AS; Vishnubhatla S; Pandey AK; Bal CS; Kumar R
Nucl Med Commun; 2017 Oct; 38(10):858-867. PubMed ID: 28817456
[TBL] [Abstract][Full Text] [Related]
55. The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial.
Capitanio U; Pepe G; Incerti E; Larcher A; Trevisani F; Lucianò R; Mapelli P; Bettinardi V; Monterisi C; Necchi A; Cascinu S; Bernardi R; Bertini R; Doglioni C; Gianolli L; Salonia A; Picchio M; Montorsi F
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):554-560. PubMed ID: 32638098
[TBL] [Abstract][Full Text] [Related]
56. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
Li X; Zhang H; Xing L; Ma H; Xie P; Zhang L; Xu X; Yue J; Sun X; Hu X; Chen M; Xu W; Chen L; Yu J
Radiother Oncol; 2012 Feb; 102(2):246-50. PubMed ID: 22100657
[TBL] [Abstract][Full Text] [Related]
57. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
58. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT
Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234
[TBL] [Abstract][Full Text] [Related]
59. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
[TBL] [Abstract][Full Text] [Related]
60. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic
Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D
Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]